2
|
Lipitz-Snyderman A, Chimonas S, Mailankody S, Kim M, Silva N, Kriplani A, Saltz LB, Sihag S, Tan CR, Widmar M, Zauderer M, Weingart S, Perchick W, Roman BR. Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations. Cancer Med 2023; 12:8063-8072. [PMID: 36737878 PMCID: PMC10134380 DOI: 10.1002/cam4.5598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 12/08/2022] [Accepted: 12/17/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Data on the clinical value of second opinions in oncology are limited. We examined diagnostic and treatment changes resulting from second opinions and the expected impact on morbidity and prognosis. METHODS This retrospective cohort study included patients presenting in 2018 to a high-volume cancer center for second opinions about newly diagnosed colorectal, head and neck, lung, and myeloma cancers or abnormal results. Two sub-specialty physicians from each cancer type reviewed 30 medical records (120 total) using a process and detailed data collection guide meant to mitigate institutional bias. The primary outcome measure was the rate of treatment changes that were "clinically meaningful", i.e., expected to impact morbidity and/or prognosis. Among those with treatment changes, another outcome measure was the rate of clinically meaningful diagnostic changes that led to treatment change. RESULTS Of 120 cases, forty-two had clinically meaningful changes in treatment with positive expected outcomes (7 colorectal, 17 head and neck, 11 lung, 7 myeloma; 23-57%). Two patients had negative expected outcomes from having sought a second opinion, with worse short-term morbidity and unchanged long-term morbidity and prognosis. All those with positive expected outcomes had improved expected morbidity (short- and/or long-term); 11 (0-23%) also had improved expected prognosis. Nine involved a shift from treatment to observation; 21 involved eliminating or reducing the extent of surgery, compared to 6 adding surgery or increasing its extent. Of the 42 with treatment changes, 13 were due to clinically meaningful diagnostic changes (1 colorectal, 5 head and neck, 3 lung, 4 myeloma; 3%-17%) . CONCLUSIONS Second-opinion consultations sometimes add clinical value by improving expected prognoses; more often, they offer treatment de-escalations, with corresponding reductions in expected short- and/or long-term morbidity. Future research could identify subgroups of patients most likely to benefit from second opinions.
Collapse
Affiliation(s)
- Allison Lipitz-Snyderman
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Susan Chimonas
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Sham Mailankody
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Michelle Kim
- Strategy and Innovation, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Nicholas Silva
- Strategy and Innovation, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Anuja Kriplani
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Leonard B Saltz
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Smita Sihag
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Carlyn Rose Tan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Maria Widmar
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Marjorie Zauderer
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Saul Weingart
- Rhode Island Hospital and Hasbro Children's Hospital, Providence, Rhode Island, USA
| | - Wendy Perchick
- Strategy and Innovation, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Benjamin R Roman
- Strategy and Innovation, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|
6
|
Hustinx R. Physician centred imaging interpretation is dying out - why should I be a nuclear medicine physician? Eur J Nucl Med Mol Imaging 2019; 46:2708-2714. [PMID: 31175395 DOI: 10.1007/s00259-019-04371-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Accepted: 05/23/2019] [Indexed: 12/16/2022]
Abstract
Radiomics, machine learning, and, more generally, artificial intelligence (AI) provide unique tools to improve the performances of nuclear medicine in all aspects. They may help rationalise the operational organisation of imaging departments, optimise resource allocations, and improve image quality while decreasing radiation exposure and maintaining qualitative accuracy. There is already convincing data that show AI detection, and interpretation algorithms can perform with equal or higher diagnostic accuracy in various specific indications than experts in the field. Preliminary data strongly suggest that AI will be able to process imaging data and information well beyond what is visible to the human eye, and it will be able to integrate features to provide signatures that may further drive personalised medicine. As exciting as these prospects are, they currently remain essentially projects with a long way to go before full validation and routine clinical implementation. AI uses a language that is totally unfamiliar to nuclear medicine physicians, who have not been trained to manage the highly complex concepts that rely primarily on mathematics, computer sciences, and engineering. Nuclear medicine physicians are mostly familiar with biology, pharmacology, and physics, yet, considering the disruptive nature of AI in medicine, we need to start acquiring the knowledge that will keep us in the position of being actors and not merely witnesses of the wonders developed by other stakeholders in front of our incredulous eyes. This will allow us to remain a useful and valid interface between the image, the data, and the patients and free us to pursue other, one might say nobler tasks, such as treating, caring and communicating with our patients or conducting research and development.
Collapse
Affiliation(s)
- Roland Hustinx
- Division of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, Belgium. .,GIGA-CRC in vivo Imaging, University of Liège, Sart Tilman, B35, 4000, Liège, Belgium.
| |
Collapse
|
9
|
Schlemmer HP, Bittencourt LK, D’Anastasi M, Domingues R, Khong PL, Lockhat Z, Muellner A, Reiser MF, Schilsky RL, Hricak H. Global Challenges for Cancer Imaging. J Glob Oncol 2018; 4:1-10. [PMID: 30241164 PMCID: PMC6180759 DOI: 10.1200/jgo.17.00036] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Imaging plays many essential roles in nearly all aspects of high-quality cancer care. However, challenges to the delivery of optimal cancer imaging in both developing and advanced countries are manifold. Developing countries typically face dramatic shortages of both imaging equipment and general radiologists, and efforts to improve cancer imaging in these countries are often complicated by poor infrastructure, cultural barriers, and other obstacles. In advanced countries, on the other hand, although imaging equipment and general radiologists are typically accessible, the complexity of oncologic imaging and the need for subspecialists in the field are largely unrecognized; as a result, training opportunities are lacking, and there is a shortage of radiologists with the necessary subspecialty expertise to provide optimal cancer care and participate in advanced clinical research. This article is intended to raise awareness of these challenges and catalyze further efforts to address them. Some promising strategies and ongoing efforts are reviewed, and some specific actions are proposed.
Collapse
Affiliation(s)
- Heinz-Peter Schlemmer
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Leonardo K. Bittencourt
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Melvin D’Anastasi
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Romeu Domingues
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Pek-Lan Khong
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Zarina Lockhat
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Ada Muellner
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Maximilian F. Reiser
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Richard L. Schilsky
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| | - Hedvig Hricak
- Heinz-Peter Schlemmer, German Cancer Research Center,
Heidelberg; Melvin D’Anastasi and Maximilian F.
Reiser, Ludwig-Maximilians-University Hospital, Munich, Germany;
Leonardo K. Bittencourt, Fluminense Federal University,
Niterói; Leonardo K. Bittencourt and Romeu
Domingues, Clínica de Diagnóstico por Imagem
(CDPI/Dasa), Rio de Janeiro, Brazil; Pek-Lan Khong, University of
Hong Kong, Queen Mary Hospital, Hong Kong, China; Zarina Lockhat,
University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;
Ada Muellner and Hedvig Hricak, Memorial Sloan
Kettering Cancer Center, New York, NY; and Richard L. Schilsky,
American Society of Clinical Oncology, Alexandria, VA
| |
Collapse
|
12
|
Horvat JV, D'Alessio DD, Bernard-Davila B, Martinez DF, Morris EA. Second opinion interpretation of breast ultrasound images-Is it worth another look? Clin Imaging 2018; 52:79-87. [PMID: 30005207 DOI: 10.1016/j.clinimag.2018.06.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 06/01/2018] [Accepted: 06/14/2018] [Indexed: 10/28/2022]
Abstract
PURPOSE To determine if real-time breast ultrasound (RTUR) after second opinion reinterpretation of submitted static ultrasound images at a comprehensive cancer center impacts clinical management, specifically by detecting additional cancer and preventing unnecessary biopsy. MATERIALS AND METHODS In this IRB-approved and HIPAA-compliant retrospective study, 209 patients were included who had breast ultrasound studies from outside facilities submitted for second opinion review between January 2013 and May 2014, and who subsequently underwent RTUR at our institution within three months of the outside study. Findings on submitted exams were compared with those on RTUR and disagreements between them were annotated to indicate the presence or absence of suspicious lesions and recommendation for biopsy. Changes in management were defined as any additional biopsies performed or biopsies averted after RTUR and reported as frequencies and percentages using 95% confidence intervals. RESULTS Following RTUR, 49 additional biopsies were performed in 43/209 patients (20.6%; 95% CI 15.1-26.1%). Additional cancer was found in 12/49 (24.5%) biopsies in 11/209 patients (5.3%; 95% CI 2.2-8.2%). Forty biopsies in 31/209 (14.8%; CI 10.0-19.7%) patients originally recommended were canceled after RTUR. Overall, a change in management after RTUR was observed in 68/209 patients (32.5%; 95% CI 26.1-38.9%), including patients with either additional biopsies performed or biopsies averted. CONCLUSION RTUR was found to be an important tool in the management of patients at our comprehensive cancer center. Although additional false-positive lesions may be detected on RTUR, a great number of patients will benefit from RTUR in finding additional cancers or avoiding unnecessary biopsies.
Collapse
Affiliation(s)
- Joao V Horvat
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
| | - Donna D D'Alessio
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
| | - Blanca Bernard-Davila
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
| | - Danny F Martinez
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
| | - Elizabeth A Morris
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
| |
Collapse
|